How should hypomagnesaemia be investigated and treated?

John Ayuk, Neil Gittoes

Research output: Contribution to journalArticle

37 Citations (Scopus)


Hypomagnesaemia is relatively common, with an estimated prevalence in the general population ranging from 2·5% to 15%. It may result from inadequate magnesium intake, increased gastrointestinal or renal loss or redistribution from extracellular to intracellular space. Drug-induced hypomagnesaemia, particularly related to proton pump inhibitor (PPI) therapy, is being increasingly recognized. Most patients with hypomagnesaemia are asymptomatic; symptomatic magnesium depletion is often associated with multiple other biochemical abnormalities, including hypokalaemia, hypocalcaemia and metabolic acidosis. Manifestations of symptomatic hypomagnesaemia most often involve neuromuscular, cardiovascular and metabolic features. Patients with symptomatic hypomagnesaemia should be treated with intravenous magnesium, reserving oral replacement for asymptomatic patients.
Original languageEnglish
Pages (from-to)743-6
Number of pages4
JournalClinical Endocrinology
Issue number6
Publication statusPublished - 1 Dec 2011


Dive into the research topics of 'How should hypomagnesaemia be investigated and treated?'. Together they form a unique fingerprint.

Cite this